Treatment Considerations for Patients With Metastatic Urothelial Carcinoma
Sumanta K. Pal, MD, associate professor of the Department of Medical Oncology and Experimental Therapeutics at City of Hope, discusses the data he considers when treating patients with metastatic urothelial carcinoma.
Sumanta K. Pal, MD, associate professor of the Department of Medical Oncology and Experimental Therapeutics at City of Hope, discusses the data he considers when treating patients with metastatic urothelial carcinoma.
While many agents have been approved for this disease, Pal says the decision will rely heavily on the physician’s comfort level with each of the agents when deciding which to use.
In Pal’s opinion, there is the highest amount of evidence with atezolizumab (Tecentriq) and pembrolizumab (Keytruda). When looking at data for atezolizumab from the IMvigor211 trial, many physicians found the results to be negative. However, one particular subset of patients in this study was given atezolizumab in comparison to agents like taxanes.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
